[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632647":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":141,"collaborators":143,"id":156,"slug":20,"hasResults":157,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":163,"sex":164,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":20,"studyType":170,"phases":171,"briefSummary":173,"conditions":174,"keywords":177,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},{"fullName":5,"class":6},"University of Colorado, Denver","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Psilocybin","EXPERIMENTAL","Two escalating doses of psilocybin 30 days apart",[13],"Drug: Psilocybin (Usona Institute)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Psilocybin (Usona Institute)","Evaluate the safety and tolerability of psychedelic administration in two cohorts of healthy older adults.\n\n* Cohort 1a Psilocybin Moderate Dose: 2 doses of oral psilocybin (10mg and then 25mg) 30 days apart.\n* Cohort 1b Psilocybin High Dose: 2 doses of oral psilocybin (15mg and then 30mg) 30 days apart.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Mary P Mancuso, MA (dual degrees)","CONTACT","3037245729","inspire@cuanschutz.edu",{"name":28,"role":24,"phone":20,"phoneExt":20,"email":29},"Lila Harris, BS","lila.m.harris@cuanschutz.edu",[31,52,70,91,107,125],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"University of California San Francisco (UCSF) Department of Neurology","RECRUITING","San Francisco","California","94158","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-122.41942,37.77493,{"lat":43,"lon":42},[46,50],{"name":47,"role":24,"phone":48,"phoneExt":20,"email":49},"Jennifer Mitchell, PhD","510-985-3522","psy.elder@ucsf.edu",{"name":47,"role":51,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":53,"status":33,"city":54,"state":55,"zip":56,"country":37,"countryCode":38,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"University of Colorado Anschutz Medical Campus","Aurora","Colorado","80045",{"type":40,"coordinates":58},[59,60],-104.83192,39.72943,{"lat":60,"lon":59},[63,66,68],{"name":64,"role":24,"phone":65,"phoneExt":20,"email":26},"Mary Mancuso, MS","303-724-5729",{"name":67,"role":24,"phone":20,"phoneExt":20,"email":20},"Lila Harris, BA",{"name":69,"role":51,"phone":20,"phoneExt":20,"email":20},"Stacy Fischer, MD",{"facility":71,"status":33,"city":72,"state":73,"zip":74,"country":37,"countryCode":38,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Emory University Brain Health Center","Atlanta","Georgia","30329",{"type":40,"coordinates":76},[77,78],-84.38798,33.749,{"lat":78,"lon":77},[81,85,89],{"name":82,"role":24,"phone":83,"phoneExt":20,"email":84},"Tanja Mletzko, MA","404-778-6663","study@emory.edu",{"name":86,"role":24,"phone":87,"phoneExt":20,"email":88},"Joyelle Van Eron, MPH","404-727-8966","jvanero@emory.edu",{"name":90,"role":51,"phone":20,"phoneExt":20,"email":20},"Ali John Zarrabi, MD",{"facility":92,"status":33,"city":93,"state":94,"zip":95,"country":37,"countryCode":38,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":40,"coordinates":97},[98,99],-71.05977,42.35843,{"lat":99,"lon":98},[102,105],{"name":103,"role":24,"phone":20,"phoneExt":20,"email":104},"Gabriel Najarian","patresearch@dfci.harvard.edu",{"name":106,"role":51,"phone":20,"phoneExt":20,"email":20},"Yvan Beaussant, MD",{"facility":108,"status":109,"city":110,"state":111,"zip":112,"country":37,"countryCode":38,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"University of Nebraska Medical Center","NOT_YET_RECRUITING","Omaha","Nebraska","68105",{"type":40,"coordinates":114},[115,116],-95.94043,41.25626,{"lat":116,"lon":115},[119,123],{"name":120,"role":24,"phone":121,"phoneExt":20,"email":122},"Jennifer Wettschreck, MS","402-559-3342","jemurray@unmc.edu",{"name":124,"role":51,"phone":20,"phoneExt":20,"email":20},"Lou Lukas, MD",{"facility":126,"status":109,"city":127,"state":127,"zip":128,"country":37,"countryCode":38,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"New York University Langone Health, Center for Psychedelic Medicine","New York","10016",{"type":40,"coordinates":130},[131,132],-74.00597,40.71427,{"lat":132,"lon":131},[135,139],{"name":136,"role":24,"phone":137,"phoneExt":20,"email":138},"Denise Balili, MS","646-501-2623","denise.balili@nyulangone.org",{"name":140,"role":51,"phone":20,"phoneExt":20,"email":20},"Stephen Ross, MD",{"type":142,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[144,147,149,151,152,154],{"name":145,"class":146},"National Institute on Aging (NIA)","NIH",{"name":148,"class":6},"University of California, San Francisco",{"name":150,"class":6},"Emory University",{"name":92,"class":6},{"name":153,"class":6},"NYU Langone Health",{"name":155,"class":6},"University of Nebraska","100632647",false,"NCT07516405","Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","Psil-Pk","Inclusion Criteria:\n\n* Aged 65-85 years \\& be male, female, or non-binary\n* Generally healthy\n* Have an identified support person\n* Capacity to Consent\n\nExclusion Criteria:\n\n* Unstable medical condition\n* Risk for hypertensive crisis (screening blood pressure \\>140\u002F90 mmHg)\n* Significant central nervous system (CNS) pathology\n* Primary psychotic or affective psychotic disorders\n* Family history of psychotic or serious bipolar spectrum illnesses\n* High risk of adverse emotional or behavioral reaction\n* Active substance use disorders (SUDs)\n* Extensive use of serotonergic hallucinogens\n* High risk of completed suicide\n* History of hallucinogen persisting perception disorder (HPPD)\n* Concurrent Medications: centrally-acting serotonergic agents; antipsychotics; certain mood stabilizers, aldehyde dehydrogenase inhibitors; significant inhibitors of UGT 1A9 or UGT 1A10\n* Certain psychiatric conditions\n* Presence of relevant finding (psychological, physical symptom, medication) prior to dosing that would make a participant unsuitable for the study",true,"ALL","65 Years","85 Years",{"count":168,"type":169},40,"ESTIMATED","INTERVENTIONAL",[172],"PHASE1","This study plans to learn more about the safety and tolerability of psychedelic administration (psilocybin) in healthy older adults ages 65-85.",[175,176],"Healthy Volunteer","Older Adults (65-85 Years)",[178,179,180],"healthy older adults ages 65-85","psilocybin safety","psilocybin tolerability","2026-06-29",{"date":183,"type":184},"2026-06-30","ACTUAL",{"date":186,"type":184},"2026-04-01",{"date":188,"type":169},"2028-03",{"name":5,"class":6},6]